Citiholin u neurologiji i psihijatriji
Citiholin u medicini
Sažetak
Citiholin je suplement-nootripik sa potencijalnom primenom u terapiji brojnih bolesti i stanja u neurologiji, psihijatriji i drugim granama medicine. Postoje eksperimentalni i klinički dokazi o koristi citiholina kod osoba nakon moždanog udara (MU), traume mozga i kognitivnog pada različitih etiologija. Rezultati prekliničkih studija ukazuju na neuroprotektivna i neurorestorativna dejstva citiholina, koja se mogu objasniti njegovim antioksidantnim, antiinflamatornim i metaboličkim dejstvima. Citiholin je neophodan za sintezu i stabilizaciju bioloških membrana, pobolјšava rad mitohondrija i neophodan je za sintezu acetilholina i drugih neurotransmitera u centralnom nervnom sistemu. Za terapiju kognitivnih sekvela MU i traume mozga ne postoje specifični lekovi, a citiholin u eksperimentalnim i kliničkim ispitivanjima pokazuje bezbedan profil sa pozitivnim kliničkim efektom na opšte kognitivne sposobnosti, pažnju, egzekutivne funkcije i raspoloženje. Takodje postoje pozitivni rezultati njegove upotrebe kod bolesnika sa neurodegenerativnim bolestima, mada na malom broju ispitanika. U psihijatriji, opisuju se pozitivni efekti citiholina na depresivnost, negativne simptome shizofrenije i u bolestima zavisnosti. U ovom preglednom radu dajemo prikaz mehanizama dejstva citiholina i sumiramo do sada objavljena istraživanja o primeni citiholina u neurologiji i psihijatriji.
Reference
Synoradzki K, Grieb P. Citicoline: A Superior Form of Choline? Nutrients 2019;11(7):1569. doi:10.3390/nu11071569. PMID:31336819.
Pavlović DM, Pavlović AM. Više kortikalne funkcije. Beograd. Orion Art; 2016.
Abdel-Aziz N, Moustafa EM, Saada HN. The impact of citicoline on brain injury in rats subjected to head irradiation. Environ Sci Pollut Res Int 2021;28(8):9742-52. doi: 10.1007/s11356-020-11101-7. PMID: 33155111.
Jasielski P, Piędel F, Piwek M, Rocka A, Petit V, Rejdak K. Application of Citicoline in Neurological Disorders: A Systematic Review. Nutrients 2020;12(10):3113. doi: 10.3390/nu12103113. PMID: 33053828.
Abdolmaleki A, Moghimi A, Ghayour MB, Rassouli MB. Evaluation of neuroprotective, anticonvulsant, sedative and anxiolytic activity of citicoline in rats. Eur J Pharmacol 2016 15;789:275-9. doi: 10.1016/j.ejphar.2016.07.048. PMID: 27475676.
Faiq MA, Wollstein G, Schuman JS, Chan KC. Cholinergic nervous system and glaucoma: From basic science to clinical applications. Prog Retin Eye Res 2019;72:100767. doi: 10.1016/j.preteyeres.2019.06.003. PMID: 31242454.
Al-Kuraishy HM, Al-Buhadily AK, Al-Gareeb AI, et al. Citicoline and COVID-19: vis-à-vis conjectured. Naunyn Schmiedebergs Arch Pharmacol 2022;395(12):1463-75. doi: 10.1007/s00210-022-02284-6. PMID: 36063198.
Cho JH, Kim JY. Efficacy and safety of oral citicoline in acute ischemic stroke: drug surveillance study in 4,191 cases. Methods Find Exp Clin Pharmaco 2009;31(03):171–6. doi: 10.1358/mf.2009.31.3.1364241. PMID: 19536360.
Adibhatla RM, Hatcher JF, Dempsey RJ. Effects of citicoline on phospholipid and glutathione levels in transient cerebral ischemia. Stroke 2001;32(10):2376-81. doi: 10.1161/hs1001.096010. PMID: 11588329.
Adibhatla RM, Hatcher JF. Citicoline mechanisms and clinical efficacy in cerebral ischemia. J Neurosci Res 2002;70(2):133-9. doi: 10.1002/jnr.10403. PMID: 12271462.
Gutiérrez-Fernández M, Rodríguez-Frutos B, Fuentes B et al. CDP-choline treatment induces brain plasticity markers expression in experimental animal stroke. Neurochem Int 2012;60(03):310–7. doi: 10.1016/j.neuint.2011.12.015. PMID: 22226841.
Piamonte BLC, Espiritu AI, Anlacan VMM. Effects of Citicoline as an Adjunct Treatment for Alzheimer's Disease: A Systematic Review. J Alzheimers Dis 2020;76(2):725-32. doi: 10.3233/JAD-200378. PMID: 32538854.
Krupinski J, Ferrer I, Barrachina M, Secades JJ, Mercadal J, Lozano R. CDP-choline reduces pro-caspase and cleaved caspase-3 expression, nuclear DNA fragmentation, and specific PARP-cleaved products of caspase activation following middle cerebral artery occlusion in the rat. Neuropharmacology 2002;42(6):846-54. doi: 10.1016/s0028-3908(02)00032-1. PMID: 12015211.
Ma X, Zhang H, Pan Q, et al. Hypoxia/Aglycemia-induced endothelial barrier dysfunction and tight junction protein downregulation can be ameliorated by citicoline. PLoS One 2013;8(12):e82604. doi: 10.1371/journal.pone.0082604. PMID: 24358213.
Hurtado O, Moro MA, Cárdenas A, et al. Neuroprotection afforded by prior citicoline administration in experimental brain ischemia: effects on glutamate transport. Neurobiol Dis 2005;18(2):336-45. doi: 10.1016/j.nbd.2004.10.006. PMID: 15686962.
Secades JJ. Role of citicoline in the management of traumatic brain injury. Pharmaceuticals (Basel) 2021;14(5):410. doi: 10.3390/ph14050410. PMID: 33926011.
Martynov MY, Gusev EI. Current knowledge on the neuroprotective and neuroregenerative properties of citicoline in acute ischemic stroke. J Exp Pharmacol 2015;7:17-28. doi: 10.2147/JEP.S63544. PMID: 27186142.
Grieb P. Neuroprotective properties of citicoline: facts, doubts and unresolved issues. CNS Drugs 2014;28(3):185-93. doi: 10.1007/s40263-014-0144-8. PMID: 24504829.
Alshammari D. Role of citicoline in modulation of angiogenesis and apoptosis in vascular/human brain microvessel endothelial cells. Ph. D. Thesis. School of Healthcare Sciences Manchester Metropolitan University; 2014.
Warach S, Pettigrew LC, Dashe JF, et al. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Citicoline 010 Investigators. Ann Neurol 2000;48(5):713-22. PMID: 11079534.
Dávalos A, Alvarez-Sabín J, Castillo J, et al; International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet 2012;380(9839):349-57. doi: 10.1016/S0140-6736(12)60813-7. PMID: 22691567.
Mehta A, Mahale R, Buddaraju K, Javali M, Acharya P, Srinivasa R. Efficacy of Neuroprotective Drugs in Acute Ischemic Stroke: Is It Helpful? J Neurosci Rural Pract 2019;10(4):576-81. doi: 10.1055/s-0039-1700790. PMID: 31831974.
Ghosh S, Das SK, Nath T, Ghosh KC, Bhattacharyya R, Mondal GP. The effect of citicoline on stroke: A comparative study from the Eastern part of India. Neurol India 2015;63(5):697-701. doi: 10.4103/0028-3886.166538. PMID: 26448227.
Martí-Carvajal AJ, Valli C, Martí-Amarista CE, Solà I, Martí-Fàbregas J, Bonfill Cosp X. Citicoline for treating people with acute ischemic stroke. Cochrane Database Syst Rev 2020;8(8):CD013066. doi: 10.1002/14651858.CD013066.pub2. PMID: 32860632.
Secades JJ, Alvarez-Sabín J, Rubio F, Lozano R, Dávalos A, Castillo J; Trial Investigators. Citicoline in intracerebral haemorrhage: a double-blind, randomized, placebo-controlled, multi-centre pilot study. Cerebrovasc Dis 2006;21(5-6):380-5. doi: 10.1159/000091547. PMID: 16490951.
Bonvicini M, Travaglini S, Lelli D, Antonelli Incalzi R, Pedone C. Is Citicoline Effective in Preventing and Slowing Down Dementia?-A Systematic Review and a Meta-Analysis. Nutrients 2023;15(2):386. doi: 10.3390/nu15020386. PMID: 36678257.
Verdelho A, Biessels GJ, Chabriat H, et al. Cerebrovascular disease in patients with cognitive impairment: A white paper from the ESO dementia committee – A practical point of view with suggestions for the management of cerebrovascular diseases in memory clinics. Eur Stroke J 2021a;6(2):111-119. doi: 10.1177/2396987321994294.
Mijajlović MD, Pavlović A, Brainin M, et al. Post-stroke dementia - a comprehensive review. BMC Med 2017;15(1):11.
Verdelho A, Wardlaw J, Pavlovic A, et al. Cognitive impairment in patients with cerebrovascular disease: A white paper from the ESO Dementia Committee. A practical point of view for stroke clinicians from the ESO Dementia Committee. Eur Stroke J 2021b;6(1):5-17. doi: 10.1177/23969873211000258. PMID: 33817330.
Alvarez-Sabín J, Ortega G, Jacas C, et al. Long-term treatment with citicoline may improve poststroke vascular cognitive impairment. Cerebrovasc Dis 2013;35(2):146-54. doi: 10.1159/000346602. PMID: 23406981.
Pavlović A, Pavlović D, Aleksić V, Šternić N. Vaskulna demencija: istine i kontroverze. Srp Arh Celok Lek 2013;141(3-4):247-55. doi: 10.2298/sarh1304247p. PMID: 23745353.
Gareri P, Cotroneo AM, Orsitto G, Putignano S. The Importance of Citicoline in Combined Treatment in Dementia: What did the Citimem Study Teach us? Rev Recent Clin Trials 2021;16(2):126-30. doi: 10.2174/1574887115999201126205538. PMID: 33243132.
Castagna A, Manzo C, Fabbo A, Lacava R, Ruberto C, Ruotolo G. The CITIMERIVA Study: CITIcoline plus MEmantina plus RIVAstigmine in Older Patients Affected with Alzheimer's Disease. Clin Drug Investig 2021;41(2):177-82. doi: 10.1007/s40261-020-00996-2. Erratum in: Clin Drug Investig. 2021 Apr;41(4):413. PMID: 33484469.
Nakazaki E, Mah E, Sanoshy K, Citrolo D, Watanabe F. Citicoline and memory function in healthy older adults: A randomized, double-blind, placebo-controlled clinical trial. J Nutr 2021;151(8):2153-60. doi: 10.1093/jn/nxab119. PMID: 33978188.
Que DS, Jamora RDG. Citicoline as Adjuvant Therapy in Parkinson's Disease: A Systematic Review. Clin Ther 2021;43(1):e19-e31. doi: 10.1016/j.clinthera.2020.11.009. PMID: 33279231.
Pavlovic D, Pekic S, Stojanovic M, Popovic V. Traumatic brain injury: neuropathological, neurocognitive and neurobehavioral sequelae. Pituitary 2019;22(3):270-82. doi: 10.1007/s11102-019-00957-9. PMID: 30929221.
Puffer RC, Yue JK, Mesley M, et al. Recovery Trajectories and Long-Term Outcomes in Traumatic Brain Injury: A Secondary Analysis of the Phase 3 Citicoline Brain Injury Treatment Clinical Trial. World Neurosurg 2019;125:e909-e915. doi: 10.1016/j.wneu.2019.01.207. PMID: 30763755.
Arcadi FA, Corallo F, Torrisi M, et al. Role of citicoline and choline in the treatment of post-stroke depression: an exploratory study. J Int Med Res 2021;49(11):3000605211055036. doi: 10.1177/03000605211055036. PMID: 34727752.
Pavlović DM. Ortomolekularna neurologija i psihijatrija. Kako pobolјšati rad mozga uz pomoć suplemenata/mikronutrijenata. Beograd. OrionArt; 2019.
Al-Kuraishy HM, Al-Gareeb AI. Citicoline Improves Human Vigilance and Visual Working Memory: The Role of Neuronal Activation and Oxidative Stress. Basic Clin Neurosci 2020;11(4):423-32. doi: 10.32598/bcn.11.4.1097.1. PMID: 33613880.
Silveri MM, Dikan J, Ross AJ, et al. Citicoline enhances frontal lobe bioenergetics as measured by phosphorus magnetic resonance spectroscopy. NMR Biomed 2008;21(10):1066-75. doi: 10.1002/nbm.1281. PMID: 18816480.
Ghajar A, Gholamian F, Tabatabei-Motlagh M, et al. Citicoline (CDP-choline) add-on therapy to risperidone for treatment of negative symptoms in patients with stable schizophrenia: A double-blind, randomized placebo-controlled trial. Hum Psychopharmacol 2018;33(4):e2662. doi: 10.1002/hup.2662. PMID: 29901250.
Jeong H, Yoon S, Sung YH, et al. Effects of cytidine-5'-diphosphate choline on gray matter volumes in methamphetamine-dependent patients: A randomized, double-blind, placebo-controlled study. J Psychiatr Res 2021;143:215-21. doi: 10.1016/j.jpsychires.2021.09.006. PMID: 34507102.
Lassi DLS, Malbergier A, Negrão AB, Florio L, De Aquino JP, Castaldelli-Maia JM. Pharmacological Treatments for Cocaine Craving: What Is the Way Forward? A Systematic Review. Brain Sci 2022;12(11):1546. doi: 10.3390/brainsci12111546. PMID: 36421870.
Fischler PV, Soyka M, Seifritz E, Mutschler J. Off-label and investigational drugs in the treatment of alcohol use disorder: A critical review. Front Pharmacol 2022;13:927703. doi: 10.3389/fphar.2022.927703. PMID: 36263121.
Skripuletz T, Manzel A, Gropengießer K, et al. Pivotal role of choline metabolites in remyelination. Brain 2015;138(Pt 2):398-413. doi: 10.1093/brain/awu358. PMID: 25524711.
Aslan E, Kocaeli H, Bekar A, Tolunay S, Ulus IH. CDP-choline and its endogenous metabolites, cytidine and choline, promote the nerve regeneration and improve the functional recovery of injured rat sciatic nerves. Neurol Res 2011;33(7):766-73. doi: 10.1179/1743132811Y.0000000004. PMID: 21756558.
Gundogdu EB, Bekar A, Turkyilmaz M, Gumus A, Kafa IM, Cansev M. CDP-choline modulates matrix metalloproteinases in rat sciatic injury. J Surg Res 2016;200(2):655-63. doi: 10.1016/j.jss.2015.10.003. PMID: 26521098.
Kanat O, Bagdas D, Ozboluk HY, Gurun MS. Preclinical evidence for the antihyperalgesic activity of CDP-choline in oxaliplatin-induced neuropathic pain. J BUON 2013;18(4):1012-8. Erratum in: J BUON. 2014 Jan-Mar;19(1):323. Kanat, D [corrected to Kanat, O]. PMID: 24344031.
Bagdas D, Sonat FA, Hamurtekin E, Sonal S, Gurun MS. The antihyperalgesic effect of cytidine-5'-diphosphate-choline in neuropathic and inflammatory pain models. Behav Pharmacol 2011p;22(5-6):589-98. doi: 10.1097/FBP.0b013e32834a1efb. PMID: 21836465.
Gandolfi S, Marchini G, Caporossi A, Scuderi G, Tomasso L, Brunoro A. Cytidine 5'-Diphosphocholine (Citicoline): Evidence for a Neuroprotective Role in Glaucoma. Nutrients 2020;12(3):793. doi: 10.3390/nu12030793. PMID: 32197303.
Rossetti L, Iester M, Tranchina L, et al. Can Treatment With Citicoline Eyedrops Reduce Progression in Glaucoma? The Results of a Randomized Placebo-controlled Clinical Trial. J Glaucoma 2020;29(7):513-20. doi: 10.1097/IJG.0000000000001565. PMID: 32541370.
Gareri P, Castagna A, Cotroneo AM, Putignano S, De Sarro G, Bruni AC. The role of citicoline in cognitive impairment: pharmacological characteristics, possible advantages, and doubts for an old drug with new perspectives. Clin Interv Aging 2015;10:1421-9. doi: 10.2147/CIA.S87886. Erratum in: Clin Interv Aging. 2015;10:1625. PMID: 26366063.
Sva prava zadržana (c) 2023 Engrami
Ovaj rad je pod Creative Commons Autorstvo-Deli pod istim uslovima 4.0 međunarodnom licencom.